Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC

June 2-6, 2017; Chicago, Illinois
Addition of veliparib and carboplatin to neoadjuvant T → AC did not increase pCR rate over carboplatin plus T → AC alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 255 KB
Released: June 7, 2017


Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Downloadable slideset with the latest expert insights on CDK4/6 inhibitors for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

Key takeaways from international and US experts on CDK4/6 inhibitors for HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.